ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 58.9 Cr.
- Current Price ₹ 45.1
- High / Low ₹ 92.2 / 44.5
- Stock P/E
- Book Value ₹ 65.7
- Dividend Yield 0.00 %
- ROCE 8.92 %
- ROE -0.21 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.69 times its book value
Cons
- Company has low interest coverage ratio.
- Promoters have pledged 44.9% of their holding.
- Earnings include an other income of Rs.9.74 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|
154 | 354 | 220 | 148 | |
140 | 286 | 205 | 152 | |
Operating Profit | 14 | 68 | 15 | -4 |
OPM % | 9% | 19% | 7% | -3% |
1 | 1 | 10 | 10 | |
Interest | 4 | 9 | 12 | 9 |
Depreciation | 1 | 6 | 9 | 9 |
Profit before tax | 10 | 54 | 3 | -12 |
Tax % | 31% | 25% | 110% | |
7 | 40 | -0 | -11 | |
EPS in Rs | 5.26 | 31.02 | -0.20 | -8.51 |
Dividend Payout % | -0% | 3% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -46% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -216% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 9% |
1 Year: | -40% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|
Equity Capital | 10 | 13 | 13 |
Reserves | 73 | 73 | 73 |
77 | 73 | 72 | |
130 | 119 | 111 | |
Total Liabilities | 290 | 278 | 269 |
93 | 88 | 86 | |
CWIP | -0 | -0 | -0 |
Investments | 0 | 0 | 0 |
198 | 190 | 184 | |
Total Assets | 290 | 278 | 269 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
25 | 26 | ||
-44 | -9 | ||
20 | -17 | ||
Net Cash Flow | 0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
Debtor Days | 105 | 138 | |
Inventory Days | 59 | 118 | |
Days Payable | 113 | 165 | |
Cash Conversion Cycle | 51 | 91 | |
Working Capital Days | 78 | 114 | |
ROCE % | 9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Copies of Newspaper Advertisements of Unaudited Financial Results as on 31.12.2023.
- Disclosure Of Unaudited Financial Results For Quarter And Nine Months Ended 31.12.2023. 14 Feb
- Board Meeting Outcome for Outcome Of Board Meeting 14.02.2024. 14 Feb
- Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 7 Feb
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015.
1 Feb - In reference to our letter dated 31.01.2024, ANG/23-24/BSE-149, please find herewith enclosed the additional details as per SEBI circular no. CIR/CFD/CMD/4/2015 dated Sept. 09, 2015 …
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)